As a psychiatric nurse practitioner, it is important to assess and treat pediatric patients with mood disorders in a careful and informed manner. In the case of the African American child suffering from depression, there are several patient factors to consider when making decisions about prescribing medication. These include the patient’s age, weight, and other medical conditions, as well as any potential interactions with other medications.
Decision #1:
The decision I have selected is to prescribe fluoxetine, a selective serotonin reuptake inhibitor (SSRI), for the patient’s depression. This decision is based on several factors, including the patient’s age, weight, and overall health, as well as the efficacy and safety of SSRIs in treating pediatric depression.
According to the American Academy of Child and Adolescent Psychiatry (AACAP), SSRIs are considered first-line treatments for depression in children and adolescents (AACAP, 2018). Studies have shown that SSRIs are effective in treating pediatric depression, and the risk of serious side effects is low when these medications are used appropriately (AACAP, 2018).
I did not select the other two options provided in the exercise because they either have limited efficacy in treating pediatric depression or have a higher risk of serious side effects. For example, tricyclic antidepressants (TCAs) are not recommended for pediatric depression due to their potential for cardiac toxicity and other serious side effects (AACAP, 2018). Bupropion is also not recommended for pediatric depression due to its potential to increase the risk of seizures in children (AACAP, 2018).
By selecting fluoxetine, I hope to achieve a reduction in the patient’s depressive symptoms and an improvement in overall quality of life. I will monitor the patient closely for any potential side effects, including suicidal ideation or behavior, and will communicate regularly with the patient and family members to ensure that they understand the risks and benefits of the medication.
Ethical considerations that may impact my treatment plan and communication with patients include informed consent, confidentiality, and the need for ongoing monitoring and communication. For example, I will need to obtain informed consent from the patient and/or the patient’s parents/guardians before prescribing medication, and I will need to ensure that the patient’s confidentiality is protected. I will also need to communicate regularly with the patient and family members to monitor the patient’s response to treatment and any potential side effects.
Decision #2:
The decision I have selected is to continue the patient on fluoxetine and to increase the dose to 20 mg/day. This decision is based on the patient’s response to the medication and the fact that fluoxetine is generally well-tolerated in pediatric patients.
I did not select the other two options provided in the exercise because they either have limited efficacy in treating pediatric depression or have a higher risk of serious side effects. For example, switching to sertraline may not be necessary if the patient is already responding well to fluoxetine, and adding an atypical antipsychotic may increase the risk of serious side effects without providing significant additional benefit (AACAP, 2018).
By increasing the patient’s dose of fluoxetine, I hope to achieve a further reduction in depressive symptoms and an improvement in overall quality of life. I will continue to monitor the patient closely for any potential side effects, including suicidal ideation or behavior, and will communicate regularly with the patient and family members to ensure that they understand the risks and benefits of the medication.
Ethical considerations that may impact my treatment plan and communication with patients include the need for ongoing monitoring and communication. I will need to communicate regularly with the patient and family members to monitor the patient’s response to treatment and any potential side effects, and to ensure that they understand the importance of adhering to the medication regimen.
Decision #3:
The decision I have selected is